Company Profile

Liminal BioSciences Inc. is a Canada-based is a development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.

Employees

Sector

Biotechnology & Medical Research

More about the company

26/09/23	Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite Index	CI
26/09/23	Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).	CI
15/09/23	Liminal BioSciences Inc. - Shareholder/Analyst Call
09/08/23	Liminal BioSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/07/23	Top Midday Gainers	MT
12/07/23	Liminal BioSciences Agrees to Be Acquired by Structured Alpha for $8.50 per Share; Shares Soar Pre-Bell	MT
05/06/23	Liminal BioSciences Inc. - Shareholder/Analyst Call
02/06/23	Liminal BioSciences Provides R&D Update	CI
10/05/23	Liminal BioSciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
06/04/23	Sector Update: Healthcare Stocks Rising Late Afternoon	MT
05/04/23	Top Midday Gainers	MT
05/04/23	Liminal BioSciences Shares Soar on Structured Alpha Takeover Bid	MT
05/04/23	Toronto Stocks Retreat; WSP Global Shares Down, Plans to Buy Calibre Professionals	DJ

24/06/21	LIMINAL BIOSCIENCES : HC Wainwright Downgrades Liminal BioSciences to Neutral From Buy	MT
02/06/21	LIMINAL BIOSCIENCES : Piper Sandler Downgrades Liminal BioSciences to Neutral From Overweight, Adjusts Price Target to $4.50 From $22	MT
18/02/21	LIMINAL BIOSCIENCES : HC Wainwright Starts Liminal BioSciences at Buy with $11 Price Target	MT
21/12/20	LIMINAL BIOSCIENCES : Piper Sandler Starts Liminal BioSciences at Overweight With $22 Price Target	MT

26/09/23	Liminal BioSciences : Notice	PU
12/09/23	Liminal BioSciences : Supplement to the Arrangement Circular – Special Meeting September 2023	PU
17/08/23	Liminal BioSciences : Notice of Special Meeting of Shareholders and Management Information Circular dated August 16, 2023 - Form 6-K	PU
17/08/23	Liminal BioSciences : Form of Proxy – Special Meeting September 2023	PU
17/08/23	Liminal BioSciences : Other	PU

Manager	Title	Age	Since
Bruce Pritchard CEO	Chief Executive Officer	53	13/11/2020
Nicole Rusaw-George DFI	Director of Finance/CFO	53	02/03/2022
Marie Iskra LAW	General Counsel	50	01/09/2019

Director	Title	Age	Since
Alek Krstajic CHM	Chairman	62	01/09/2020
Eugene Siklos BRD	Director/Board Member	62	01/09/2020

Liminal BioSciences Inc. Stock

Stocks

PJ2

CA53272L2021

Biotechnology & Medical Research

Latest news : Liminal BioSciences Inc.

Analysts' recommendations: Liminal BioSciences Inc.

Press Releases: Liminal BioSciences Inc.

News in other languages: Liminal BioSciences Inc.

Managers and Directors: Liminal BioSciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/10/23	Thomvest Asset Management, Inc.	Tax	Company	17,888,516	550.4948%
01/10/23	Thomvest Asset Management, Inc.	Tax	Company	17,888,516	550.4948%
01/10/23	Thomvest Asset Management, Inc.	Marche	Company	19,876,129	611.6609%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIMINAL BIOSCIENCES INC.	-.--%	+6.09%	-	-	13.02M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+11.75%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+647.65%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.31%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+43.00%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.44%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.10%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-34.51%	12.7B
Average	+0.20%	+0.83%	+54.56%	+107.74%	27.25B
Weighted average by Cap.	+0.48%	+0.91%	+74.42%	+138.21%